Search

everythinglearnresearchcommunity

for

Search:↓

24-Hydroxycholesterol reduces DHT formation in brain cancer cells, linking cholesterol and hormone metabolism.

Androsterone and finasteride have different solid forms, with new findings correcting previous errors and identifying a new form.

SARM-induced changes in the androgen receptor are specific to each ligand and affect stability and protein interactions.

PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.

The patient's high testosterone was reduced by a medication that suppresses gonadotropin.

Finasteride reduces DHT to treat prostate issues and hair loss.

Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.

Hormonal interactions, especially involving DHT and estrogen, play a key role in BPH development and treatment.

High doses of testosterone disrupt hormone levels and receptor expression in the uterus, affecting fertility.

Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.

Spironolactone may help reduce excessive hair growth in women with high male hormone levels.

Properly administered testosterone therapy is safe and effective but often not covered by insurance.

Five preservatives may disrupt hormone function and need more health and environmental risk assessment.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.

The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

Topical 17 alpha-propylmesterolone increases hair cell growth in androgenetic alopecia.

A new compound effectively inhibits human 5α-reductase 1.

Triptorelin helps evaluate hormone production in Sertoli-Leydig cell tumors.

Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.

Finasteride, when taken daily, lowers dihydrotestosterone levels but doesn't noticeably affect adrenal steroid production, except by blocking the 5 alpha-reductase enzyme.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Estrogen deficiency can reduce the enzyme activity needed to activate vitamin D.

Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.

Finasteride reduces response to stress and rewards, affecting behavior and mental health.

Male cells need DHT to respond to testosterone, while female cells do not.

Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.

Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.